PACB (Pacific Biosciences of California, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by PACB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Mark Van Oene | See Remarks | Sell | — | — |
| 2026-08-11 | Mark Van Oene | See Remarks | A | — | — |
| 2026-06-04 | MARSHALL MOHR | Director | A | — | — |
| 2026-06-04 | JOHN F MILLIGAN | Director | A | — | — |
| 2026-06-04 | Christopher M Smith | Director | A | — | — |
| 2026-06-04 | KATHY ORDONEZ | Director | A | — | — |
| 2026-06-04 | Christopher Gibson | Director | A | — | — |
| 2026-06-04 | RANDALL S LIVINGSTON | Director | A | — | — |
| 2026-06-04 | William W. Ericson | Director | A | — | — |
| 2026-06-04 | Hannah Valantine | Director | A | — | — |
| 2026-04-10 | Christopher Gibson | Director | A | — | — |
| 2026-04-03 | James R Gibson II | See Remarks | Sell | — | — |
| 2026-03-05 | Christopher Gibson | Director | A | — | — |
| 2026-03-04 | Mark Van Oene | See Remarks | Sell | — | — |
| 2026-03-04 | CHRISTIAN O HENRY | See Remarks | Sell | — | — |
| 2026-03-04 | Michele Farmer | See Remarks | Sell | — | — |
| 2026-03-03 | Michele Farmer | See Remarks | A | — | — |
| 2026-03-03 | CHRISTIAN O HENRY | See Remarks | A | — | — |
| 2026-03-03 | James R Gibson II | See Remarks | A | — | — |
| 2026-03-03 | Mark Van Oene | See Remarks | A | — | — |
| 2026-02-19 | Michele Farmer | See Remarks | Sell | — | — |
| 2026-02-19 | CHRISTIAN O HENRY | See Remarks | Sell | — | — |
| 2026-02-19 | Mark Van Oene | See Remarks | Sell | — | — |
| 2025-08-20 | Mark Van Oene | See Remarks | Sell | — | — |
| 2025-06-06 | Hannah Valantine | Director | A | — | — |
| 2025-06-06 | JOHN F MILLIGAN | Director | A | — | — |
| 2025-06-06 | MARSHALL MOHR | Director | A | — | — |
| 2025-06-06 | William W. Ericson | Director | A | — | — |
| 2025-06-06 | KATHY ORDONEZ | Director | A | — | — |
| 2025-06-06 | Christopher M Smith | Director | A | — | — |
| 2025-06-06 | RANDALL S LIVINGSTON | Director | A | — | — |
| 2025-06-06 | Lucy Shapiro | Director | A | — | — |
| 2025-05-21 | Michele Farmer | See Remarks | Sell | — | — |
| 2025-04-02 | James R Gibson II | See Remarks | A | — | — |
| 2025-03-21 | Michele Farmer | See Remarks | A | — | — |
| 2025-03-21 | Mark Van Oene | See Remarks | A | — | — |
| 2025-03-21 | CHRISTIAN O HENRY | See Remarks | A | — | — |
| 2025-03-05 | Michele Farmer | See Remarks | Sell | — | — |
| 2025-03-05 | Mark Van Oene | See Remarks | Sell | — | — |
| 2025-03-05 | CHRISTIAN O HENRY | See Remarks | Sell | — | — |
| 2025-02-19 | CHRISTIAN O HENRY | See Remarks | Sell | — | — |
| 2025-02-19 | Michele Farmer | See Remarks | Sell | — | — |
| 2025-02-19 | Mark Van Oene | See Remarks | Sell | — | — |
| 2025-02-03 | Christopher M Smith | Director | A | — | — |
| 2025-01-10 | Mark Van Oene | See Remarks | Sell | — | — |
| 2024-10-02 | Susan G. Kim | See Remarks | Sell | — | — |
| 2024-09-17 | CHRISTIAN O HENRY | See Remarks | Sell | — | — |
| 2024-08-20 | Mark Van Oene | See Remarks | Sell | — | — |
| 2024-08-20 | Jeff Eidel | See Remarks | Sell | — | — |
| 2024-06-20 | JOHN F MILLIGAN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,890,013 | — |
| — | See Remarks | 3,581,813 | — |
| — | See Remarks | 2,705,853 | — |
| — | See Remarks | 1,245,663 | — |
| — | VP & Chief Technology Officer | 1,093,063 | — |
| — | Director | 958,154 | — |
| — | EVP, CFO and PAO | 874,812 | — |
| — | See Remarks | 869,938 | — |
| — | Chairman, CEO & President | 760,359 | — |
| — | See Remarks | 695,654 | — |
| — | Director | 403,037 | — |
| — | See Remarks | 305,948 | — |
| — | SVP, Research & Development | 249,220 | — |
| — | See Remarks | 190,280 | — |
| — | Director | 160,000 | — |
| — | SVP, Market Development | 158,174 | — |
| — | Director | 132,821 | — |
| — | Director | 132,821 | — |
| — | Director | 111,386 | — |
| — | Director | 110,504 | — |
| — | Chief Accounting Officer | 88,474 | — |
| — | Director | 65,000 | — |
| — | Director | 57,116 | — |
| — | Director | 54,099 | — |
| — | Director | 22,821 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PACB quote page; the site-wide leaderboard is on the insider transactions hub.